What's New

Last Posted: Jun 13, 2024

• Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia.
  Lauren G Banaszak et al. JCO Precis Oncol 2024 8e2300518
• Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia
  
• Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia.
  Andrew Seto et al. Cancers (Basel) 2024 16(9)
• Advancing hospital-based health technology assessment: evaluating genomic panel contracting strategies for blood tumors through a multimethodology.
  Susana Afonso et al. Int J Technol Assess Health Care 2023 39(1) e76
• The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus.
  Julie Bergeron et al. Curr Oncol 2023 30(12) 10410-10436
• Older Patients With AML Less Likely to Receive Genomic Testing, Study Finds
  P Steinzor, AJMC, August 29, 2023
• Management of Down Syndrome-Associated Leukemias: A Review.
  Anupam Verma et al. JAMA Oncol 2023
• Telomere Length and Clonal Hematopoiesis.
  George Vassiliou et al. N Engl J Med 2023 5 (26) 2481-2484
• Molecular Heterogeneity of Pediatric AML with Atypical Promyelocytes Accumulation in Children-A Single Center Experience.
  Aleksandra Borkovskaia et al. Genes 2023 14(3)
• A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms.
  Qiujin Shen et al. Cancer research communications 2023 2(4) 258-276
• The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.
  Marta Santiago et al. Cancers 2023 15(5)
• Comprehensive analysis of PTPN family expression and prognosis in acute myeloid leukemia.
  Yong Liu et al. Frontiers in genetics 2023 131087938
• Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
  Sargas Claudia et al. Cancers 2023 15(2)
• Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America.
  Gómez-De León Andrés et al. Hematology (Amsterdam, Netherlands) 2023 28(1) 2158015
• Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease.
  Fitzhugh Courtney D et al. Hematology. American Society of Hematology. Education Program 2022 2022(1) 266-271
• Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
  Ganzel Chezi et al. Leukemia research 2022 123106971
• Unified classification and risk-stratification in Acute Myeloid Leukemia.
  Tazi Yanis et al. Nature communications 2022 8 (1) 4622
• Screening a Targeted Panel of Genes by Next-Generation Sequencing Improves Risk Stratification in Real World Patients with Acute Myeloid Leukemia.
  Matos Sónia et al. Cancers 2022 14(13)
• Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia.
  Xu Zi-Jun et al. Molecular therapy oncolytics 2022 2688-104
• How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.
  Moore Jozal W et al. Current treatment options in oncology 2022
• Molecular genetic and clinical characterization of acute myeloid leukemia with trisomy 8 as the sole chromosome abnormality.
  Liu Jie et al. Hematology (Amsterdam, Netherlands) 2022 27(1) 565-574
• A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear.
  Wang Meifang et al. Frontiers in oncology 2022 12844978
• Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1-RUNX1T1 or CBFB-MYH11 fusions.
  Qin Wei et al. Turkish journal of haematology : official journal of Turkish Society of Haematology 2022
• WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients.
  Koczkodaj Dorota et al. Journal of clinical medicine 2022 11(7)
• A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients.
  Yang Min et al. Frontiers in oncology 2022 11783114
• A Machine Learning Approach to the Classification of Acute Leukemias and Distinction From Nonneoplastic Cytopenias Using Flow Cytometry Data.
  Monaghan Sara A et al. American journal of clinical pathology 2021
• Incorporating genetic counseling into the evaluation of pediatric bone marrow failure.
  Schneider Kami Wolfe et al. Journal of genetic counseling 2021
• Adult Acute Myeloid Leukemia with the KMT2A-Mixed Lineage Leukemia T10 Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway.
  Cai Xiaohui et al. Acta haematologica 2021 1-7
• Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia.
  Wang Youjin et al. Scientific reports 2021 11(1) 15004
• DNA methylation analysis improves the prognostication of acute myeloid leukemia.
  Samimi Hanie et al. EJHaem 2021 2(2) 211-218
• An overview of genetic predisposition to familial hematological malignancies.
  Hamadou Walid Sabri et al. Bulletin du cancer 2021
• Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia.
  Barnell Erica K et al. JCO precision oncology 2021 5
• Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia.
  Rivera Osvaldo D et al. Proceedings of the National Academy of Sciences of the United States of America 2021 118(15)
• Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.
  Duncavage Eric J et al. The New England journal of medicine 2021 384(10) 924-935
• [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies].
  Zhang Li-Juan et al. Zhongguo shi yan xue ye xue za zhi 2020 Dec 28(6) 1985-1990
• Informed consent for genetic testing in hematology.
  Marron Jonathan M et al. Hematology. American Society of Hematology. Education Program 2020 2020(1) 213-218
• Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
  A Burd et al, Nature Medicine, October 26, 2020
• GATA2 Related Conditions and Predisposition to Pediatric Myelodysplastic Syndromes.
  Bruzzese Antonella et al. Cancers 2020 Oct 12(10)
• Acute myeloid leukemia and artificial intelligence, algorithms and new scores.
  Radakovich Nathan et al. Best practice & research. Clinical haematology 2020 Sep 33(3) 101192
• Methylation-independent CRIP1 expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia.
  Ma Bei-Bei et al. American journal of translational research 2020 12(9) 4840-4852
• Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A .
  Bill Marius et al. Proceedings of the National Academy of Sciences of the United States of America 2020 Oct
• DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets.
  Gabellier Ludovic et al. Cancers 2020 Oct 12(10)
• Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia.
  Huang Sai et al. Frontiers in oncology 2020 101648
• Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies.
  Dou Aixia et al. Journal of cellular immunology 2020 2(5) 237-244
• The Evolving Landscape of Myelodysplastic Syndrome Prognostication.
  Shreve Jacob et al. Clinical hematology international 2020 Jun 2(2) 43-48
• Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia.
  Sha K et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 Aug
• Prognostic role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia.
  Lai Rui et al. Journal of Cancer 2020 11(17) 5150-5161
• Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
  Ni Jing et al. International journal of laboratory hematology 2020 Jul
• Monitoring and treatment of MDS in genetically susceptible persons.
  Davies Stella M et al. Hematology. American Society of Hematology. Education Program 2019 2019(1) 105-109
• Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
  Yun Seongseok et al. Leukemia research 2019 84106194
• A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.
  Kirtonia Anuradha et al. Journal of molecular medicine (Berlin, Germany) 2020 Jul
• Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study.
  Yasuda Takahiko et al. Cancer science 2020 Jul
• Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.
  Alhumaid Muhned S et al. Acta haematologica 2020 Jun 1-11
• Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia.
  Silveira Douglas R A et al. Blood advances 2020 May 4(10) 2339-2350
• A three-gene signature might predict prognosis in patients with acute myeloid leukemia.
  Zhu Xin et al. Bioscience reports 2020 May
• Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
  Short Nicholas J et al. Blood advances 2020 Apr 4(8) 1670-1677
• Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.
  Tan David Shao-Peng et al. Asia-Pacific journal of clinical oncology 2020 Apr
• Clinical application of thiopurine pharmacogenomics in pediatrics.
  Pavlovic Sonja et al. Current drug metabolism 2020 Mar
• Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia.
  Ni Jie et al. Frontiers in oncology 2019 91509
• Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France.
  Tremblay Gabriel et al. The European journal of health economics : HEPAC : health economics in prevention and care 2020 Jan
• Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
  Peterson Jess F et al. Genes, chromosomes & cancer 2019 58(8) 567-577
• Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia.
  Yu Jifeng et al. Experimental hematology & oncology 2020 92
• The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
  Lyu Mengyuan et al. Gene 2020 Feb 726144195
• Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
  Yang Fei et al. Molecular diagnosis & therapy 2019 Dec
• Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?
  Duetz Carolien et al. Current opinion in oncology 2019 Dec
• [Importance of next generation sequencing in precision oncology approach of acute myeloid leukemia].
  Andrikovics Hajnalka et al. Magyar onkologia 2019 Dec 63(4) 282-287
• Genetic predisposition to MDS: diagnosis and management.
  Furutani Elissa et al. Hematology. American Society of Hematology. Education Program 2019 Dec 2019(1) 110-119
• Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.
  Richardson Daniel R et al. Seminars in oncology nursing 2019 Nov 150957
• Clinical Validation of a Myeloid Next-Generations Sequencing Panel for Single Nucleotide Variants, Indels, and Fusion Genes.
  Izevbaye Iyare et al. The Journal of molecular diagnostics : JMD 2019 Nov
• The androgen receptor expression and association with patient's survival in different cancers.
  Hu Chao et al. Genomics 2019 Nov
• Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
  Ritterhouse Lauren L et al. Molecular diagnosis & therapy 2019 Oct
• Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis.
  Zhou Ting et al. Pediatric hematology and oncology 2019 Nov 1-14
• Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.
  Carbonell Diego et al. Cancers 2019 Sep 11(9)
• Family Members at Higher Risk for Blood Cancers
  P Harrison, Medscape, September 9, 2019
• [Precision medicine for acute myeloid leukemia based on genomic profiling].
  Sanada Masashi et al. [Rinsho ketsueki] The Japanese journal of clinical hematology 2019 60(7) 847-853
• Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.
  Tremblay Gabriel et al. Applied health economics and health policy 2019 Aug
• Genetic Testing in the Diagnosis and Biology of Acute Leukemia.
  Harris Marian H et al. American journal of clinical pathology 2019 Aug 152(3) 322-346
• Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?
  Madanat Yazan F et al. Acta medica academica 2019 Apr 48(1) 35-44
• Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.
  Clifford Maggie et al. Leukemia & lymphoma 2019 Jul 1-8
• Identifying patients with genetic predisposition to acute myeloid leukemia.
  Obrochta Ellyn et al. Best practice & research. Clinical haematology 2018 31(4) 373-378
• A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
  Drusbosky Leylah M et al. Blood advances 2019 Jun 3(12) 1837-1847
• Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
  Miyamoto Kenichi et al. International journal of clinical oncology 2019 May
• An integrative approach reveals genetic complexity and epigenetic perturbation in acute Promyelocytic leukemia: a single institution experience.
  Rahimi Nina et al. Human pathology 2019 May
• Clinical implications of molecular markers in acute myeloid leukemia.
  Kayser Sabine et al. European journal of haematology 2019 Jan 102(1) 20-35
• A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.
  Wagner Sarah et al. Blood advances 2019 Apr 3(8) 1330-1346
• Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.
  Bhatt Vijaya Raj et al. Cancer treatment reviews 2019 May 7552-61
• Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis.
  Sandner Anne-Sophie et al. PloS one 2019 14(4) e0215453
• Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
  Løvvik Juul-Dam Kristian et al. Pediatric blood & cancer 2019 Mar e27671
• A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.
  Herold Tobias et al. Haematologica 2018 103(3) 456-465
• Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
  Mistry Akshitkumar M et al. Journal of neuro-oncology 2018 Jun 138(2) 307-313
• Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
  Leisch Michael et al. Cancers 2019 Feb 11(2)
• Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.
  Wong Hong Yuen et al. Frontiers in oncology 2018 8669
• Precision medicine in the treatment stratification of AML patients: challenges and progress.
  Lohse Ines et al. Oncotarget 2018 Dec 9(102) 37790-37797
• Genetics of MDS.
  Ogawa Seishi et al. Blood 2019 Jan
• Targeting FLT3 mutations in AML: review of current knowledge and evidence.
  Daver Naval et al. Leukemia 2019 Jan
• New drugs for acute myeloid leukemia inspired by genomics and when to use them.
  Pollyea Daniel A et al. Hematology. American Society of Hematology. Education Program 2018 2018(1) 45-50
• Clinical Utility Of A Next-Generation Sequencing Panel For Acute Myeloid Leukemia Diagnostics.
  Alonso Carmen M et al. The Journal of molecular diagnostics : JMD 2018 Dec
• Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.
  Galanina Natalie et al. Cancers 2018 Dec 11(1)
• Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection.
  Patel Keyur P et al. The Journal of molecular diagnostics : JMD 2019 Jan 21(1) 89-98
• The MDS genomics-prognosis symbiosis.
  Nazha Aziz et al. Hematology. American Society of Hematology. Education Program 2018 Nov 2018(1) 270-276

More